

PART VI: SUMMARY OF THE RISK MANAGEMENT PLAN

Summary of risk management plan for Arsenic Trioxide Tillomed 2 mg/ml concentrate for solution for infusion (herein referred as Arsenic trioxide infusion):

This is a summary of the risk management plan (RMP) for Arsenic trioxide infusion. The RMP details important risks of Arsenic trioxide infusion, how these risks can be minimised, and how more information will be obtained about Arsenic trioxide infusion's risks and uncertainties (missing information).

Arsenic trioxide infusion's summary of product characteristics (SmPC) and its package leaflet (PL) give essential information to healthcare professionals and patients on how Arsenic trioxide infusion should be used.

I. The medicine and what it is used for

Arsenic trioxide is indicated for induction of remission, and consolidation in adult patients with:

- Newly diagnosed low-to-intermediate risk acute promyelocytic leukaemia (APL) (white blood cell count, $\leq 10 \times 10^3 /\mu\text{l}$) in combination with all-trans-retinoic acid (ATRA).
- Relapsed/refractory acute promyelocytic leukaemia (APL) (previous treatment should have included a retinoid and chemotherapy) characterised by the presence of the t(15;17) translocation and/or the presence of the promyelocytic leukaemia/retinoic-acid-receptor-alpha (PML/RAR-alpha) gene.

II. Risks associated with the medicine and activities to minimise or further characterise the risks

Important risks of Arsenic trioxide, together with measures to minimise such risks and the proposed studies for learning more about Arsenic trioxide's risks, are outlined below.

Measures to minimise the risks identified for medicinal products can be:

- Specific information, such as warnings, precautions, and advice on correct use, in the PL and SmPC addressed to patients and healthcare professionals;
- Important advice on the medicine's packaging;
- The authorised pack size — the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly;
- The medicine's legal status — the way a medicine is supplied to the patient (e.g. with or without prescription) can help to minimise its risks.

Together, these measures constitute routine risk minimisation measures.

In addition to these measures, information about adverse reactions is collected continuously and regularly analysed, so that immediate action can be taken as necessary. These measures constitute routine pharmacovigilance activities. If important information that may affect the safe use of arsenic trioxide is not yet available, it is listed under 'missing information' below.

II.A List of important risks and missing information

Important risks of Arsenic trioxide infusion are risks that need special risk management activities to further investigate or minimise the risk, so that the medicinal product can be safely administered. Important risks can be regarded as identified or potential. Identified risks are concerns for which there is sufficient proof of a link with the use of Arsenic trioxide infusion. Potential risks are concerns for which an association with the use of this medicine

is possible based on available data, but this association has not been established yet and needs further evaluation. Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected (e.g. on the long-term use of the medicine).

List of important risks and missing information	
Important identified risks	• None
Important potential risks	• Carcinogenicity
Missing information	• Long-term safety

II. B Summary of important risks

The safety information in the proposed Product Information is aligned to the reference medicinal product.

II.C Post-authorisation development plan

II.C.1 Studies which are conditions of the marketing authorisation

There are no studies which are conditions of the marketing authorisation or specific obligation of Arsenic Trioxide Tillomed 2 mg/ml concentrate for solution for infusion.

II.C.2 Other studies in post-authorisation development plan

There are no studies required for Arsenic Trioxide Tillomed 2 mg/ml concentrate for solution for infusion.